155 related articles for article (PubMed ID: 15837626)
1. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia.
Lugthart S; Cheok MH; den Boer ML; Yang W; Holleman A; Cheng C; Pui CH; Relling MV; Janka-Schaub GE; Pieters R; Evans WE
Cancer Cell; 2005 Apr; 7(4):375-86. PubMed ID: 15837626
[TBL] [Abstract][Full Text] [Related]
2. Building better therapy for children with acute lymphoblastic leukemia.
Carroll WL; Raetz EA
Cancer Cell; 2005 Apr; 7(4):289-91. PubMed ID: 15837616
[TBL] [Abstract][Full Text] [Related]
3. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
Stams WA; den Boer ML; Beverloo HB; Meijerink JP; van Wering ER; Janka-Schaub GE; Pieters R
Clin Cancer Res; 2005 Apr; 11(8):2974-80. PubMed ID: 15837750
[TBL] [Abstract][Full Text] [Related]
4. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment.
Holleman A; Cheok MH; den Boer ML; Yang W; Veerman AJ; Kazemier KM; Pei D; Cheng C; Pui CH; Relling MV; Janka-Schaub GE; Pieters R; Evans WE
N Engl J Med; 2004 Aug; 351(6):533-42. PubMed ID: 15295046
[TBL] [Abstract][Full Text] [Related]
5. Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia.
Styczynski J; Piatkowska M; Jaworska-Posadzy A; Czyzewski K; Kubicka M; Kolodziej B; Kurylo-Rafinska B; Debski R; Pogorzala M; Wysocki M
Anticancer Res; 2012 Dec; 32(12):5495-9. PubMed ID: 23225457
[TBL] [Abstract][Full Text] [Related]
6. Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia.
Hongo T; Yamada S; Yajima S; Watanabe C; Fujii Y; Kawasaki H; Yazaki M; Hanada R; Horikoshi Y
Int J Hematol; 1999 Dec; 70(4):268-77. PubMed ID: 10643153
[TBL] [Abstract][Full Text] [Related]
7. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia.
Kaspers GJ; Veerman AJ; Pieters R; Van Zantwijk CH; Smets LA; Van Wering ER; Van Der Does-Van Den Berg A
Blood; 1997 Oct; 90(7):2723-9. PubMed ID: 9326239
[TBL] [Abstract][Full Text] [Related]
8. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia.
Schotte D; De Menezes RX; Akbari Moqadam F; Khankahdani LM; Lange-Turenhout E; Chen C; Pieters R; Den Boer ML
Haematologica; 2011 May; 96(5):703-11. PubMed ID: 21242186
[TBL] [Abstract][Full Text] [Related]
10. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
[TBL] [Abstract][Full Text] [Related]
11. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Styczynski J; Pieters R; Huismans DR; Schuurhuis GJ; Wysocki M; Veerman AJ
Br J Haematol; 2000 Sep; 110(4):813-8. PubMed ID: 11054062
[TBL] [Abstract][Full Text] [Related]
12. Treatment of high-risk acute lymphoblastic leukemia with protocols PETHEMA LAL 7/78 and LAL 17/84.
Ortega JJ; Javier G; Olivé T
An Esp Pediatr; 1988 Oct; 29 Suppl 34():72-83. PubMed ID: 3214043
[No Abstract] [Full Text] [Related]
13. Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia.
Holleman A; den Boer ML; Kazemier KM; Janka-Schaub GE; Pieters R
Blood; 2003 Dec; 102(13):4541-6. PubMed ID: 12920041
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid excitatory amino acids and tau protein in children with acute lymphoblastic leukemia treated according to the BFM protocol.
Holownia A; Trofimiuk E; Krawczuk-Rybak M; Jakubow P; Kaliszewski J; Muszynska-Roslan K; Braszko JJ
Acta Haematol; 2004; 112(4):222-4. PubMed ID: 15564737
[No Abstract] [Full Text] [Related]
15. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
[TBL] [Abstract][Full Text] [Related]
16. Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia.
Efferth T; Sauerbrey A; Steinbach D; Gebhart E; Drexler HG; Miyachi H; Chitambar CR; Becker CM; Zintl F; Humeny A
Int J Oncol; 2003 Aug; 23(2):509-17. PubMed ID: 12851703
[TBL] [Abstract][Full Text] [Related]
17. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia.
Pieters R; Huismans DR; Loonen AH; Hählen K; van der Does-van den Berg A; van Wering ER; Veerman AJ
Lancet; 1991 Aug; 338(8764):399-403. PubMed ID: 1678081
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
[TBL] [Abstract][Full Text] [Related]
19. Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia.
Lauten M; Cario G; Asgedom G; Welte K; Schrappe M
Haematologica; 2003 Nov; 88(11):1253-8. PubMed ID: 14607754
[TBL] [Abstract][Full Text] [Related]
20. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines.
Ronghe M; Burke GA; Lowis SP; Estlin EJ
Cancer Treat Rev; 2001 Dec; 27(6):327-37. PubMed ID: 11908926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
